Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.
A case of an 82-year-old man who suffered an acute ST-elevation myocardial infarction while receiving treatment with intravenous immunoglobulin (IVIg) for thrombocytopenia is discussed. A total of 29 other cases of thromboembolism related to IVIg therapy have been reported, and the incidence seems to be especially high in elderly patients with cerebrovascular risk factors and also in patients with paraproteinemias. Possible mechanisms to account for this complication may include some of the following: platelet activation, increased blood viscosity, contamination of IVIg with activated coagulation factors, induced arterial vasospasm, production of vasoconstrictive cytokines, and vasculitis. Ten patients out of the 29 reported patients died from this serious complication. In our patient, spontaneous reperfusion occurred without any treatment and he had an uneventful outcome.
Hefer
David
D
Department of Internal Medicine, St. Luke's/Roosevelt Hospital Center, 1000 Tenth Avenue, 10019, New York, NY, USA. hefer.david@earthlink.net
Jaloudi
Mohammed
M
D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D013923:Thromboembolism / Q000097:blood / Q000209:etiology*
D016756:Immunoglobulins, Intravenous